blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3777855

EP3777855 - METHODS OF TREATMENT FOR FIBROTIC DISEASES [Right-click to bookmark this link]
Former [2021/07]METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
[2022/05]
StatusNo opposition filed within time limit
Status updated on  25.08.2023
Database last updated on 16.07.2024
FormerThe patent has been granted
Status updated on  16.09.2022
FormerGrant of patent is intended
Status updated on  08.02.2022
FormerRequest for examination was made
Status updated on  20.08.2021
FormerThe application has been published
Status updated on  15.01.2021
Most recent event   Tooltip08.12.2023Lapse of the patent in a contracting state
New state(s): LU		published on 10.01.2024  [2024/02]
Applicant(s)For all designated states
Genfit
885 avenue Eugène Avinée
59120 Loos / FR
[2021/07]
Inventor(s)01 / DARTEIL, Raphaël
48 rue Sainte Geneviève
69006 Lyon / FR
02 / WALCZAK, Robert
Résidence Parc d'Isly 13 bis rue Delezenne
59000 LILLE / FR
03 / BELANGER, Carole
3 Allée du Verger
59910 BONDUES / FR
04 / NEGRO, Emilie
662, avenue du Dr Jacques Arnaud
74190 PASSY / FR
05 / DAUBERSIES, Pierre
36 rue de la Grande Chapelle
62490 VITRY EN ARTOIS / FR
06 / DELATAILLE, Philippe
344 rue Sadi Carnot
59790 RONCHIN / FR
 [2021/12]
Former [2021/07]01 / DARTEIL, Raphaël
90 rue Edouard Vaillant
69100 VILLEURBANNE / FR
02 / WALCZAK, Robert
Résidence Parc d'Isly 13 bis rue Delezenne
59000 LILLE / FR
03 / BELANGER, Carole
3 Allée du Verger
59910 BONDUES / FR
04 / NEGRO, Emilie
662 avenue du Dr Jacques Arnaud
74190 PASSY / FR
05 / DAUBERSIES, Pierre
36 rue de la Grande Chapelle
62490 VITRY EN ARTOIS / FR
06 / DELATAILLE, Philippe
344 rue Sadi Carnot
59790 RONCHIN / FR
Representative(s)Cabinet Becker et Associés
25, rue Louis le Grand
75002 Paris / FR
[2021/07]
Application number, filing date20194458.413.03.2017
[2021/07]
Priority number, dateEP2016030542511.04.2016         Original published format: EP 16305425
[2021/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3777855
Date:17.02.2021
Language:EN
[2021/07]
Type: B1 Patent specification 
No.:EP3777855
Date:19.10.2022
Language:EN
[2022/42]
Search report(s)(Supplementary) European search report - dispatched on:EP16.12.2020
ClassificationIPC:A61K31/426, A61K45/06, A61P1/16, A61P11/00
[2021/07]
CPC:
A61K31/426 (EP,EA,IL,US); A61K45/06 (EP,EA,IL,US); A61P1/00 (EP,IL);
A61P1/04 (EP,IL); A61P1/16 (EP,EA,IL); A61P1/18 (EP,IL);
A61P11/00 (EP,EA,IL); A61P11/06 (EP,IL); A61P13/12 (EP,IL);
A61P15/00 (EP,IL); A61P17/00 (EP,IL); A61P17/02 (EP,IL);
A61P19/00 (EP,IL); A61P19/02 (EP,IL); A61P21/00 (EP,IL);
A61P25/00 (EP,IL); A61P27/02 (EP,IL); A61P29/00 (EP,IL);
A61P43/00 (EP,IL); A61P9/00 (EP,IL); A61P9/10 (EP,IL) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/38]
Former [2021/07]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON FIBROTISCHEN ERKRANKUNGEN[2022/05]
English:METHODS OF TREATMENT FOR FIBROTIC DISEASES[2022/05]
French:PROCÉDÉS DE TRAITEMENT DE MALADIES FIBROTIQUES[2022/05]
Former [2021/07]VERFAHREN ZUR BEHANDLUNG VON CHOLESTATISCHEN UND FIBROTISCHEN ERKRANKUNGEN
Former [2021/07]METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
Former [2021/07]PROCÉDÉS DE TRAITEMENT DE MALADIES CHOLESTATIQUES ET FIBROTIQUES
Examination procedure16.08.2021Amendment by applicant (claims and/or description)
16.08.2021Examination requested  [2021/38]
16.08.2021Date on which the examining division has become responsible
09.02.2022Communication of intention to grant the patent
08.07.2022Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
02.09.2022Fee for grant paid
02.09.2022Fee for publishing/printing paid
02.09.2022Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP17710285.2  / EP3442580
Opposition(s)20.07.2023No opposition filed within time limit [2023/39]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
02.09.2022Request for further processing filed
02.09.2022Full payment received (date of receipt of payment)
Request granted
16.09.2022Decision despatched
Fees paidRenewal fee
03.09.2020Renewal fee patent year 03
03.09.2020Renewal fee patent year 04
15.03.2021Renewal fee patent year 05
25.02.2022Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL19.10.2022
AT19.10.2022
EE19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
MC19.10.2022
PL19.10.2022
RO19.10.2022
RS19.10.2022
SE19.10.2022
SI19.10.2022
SK19.10.2022
SM19.10.2022
IS19.02.2023
LU13.03.2023
[2024/02]
Former [2023/51]AL19.10.2022
AT19.10.2022
EE19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
MC19.10.2022
PL19.10.2022
RO19.10.2022
RS19.10.2022
SE19.10.2022
SI19.10.2022
SK19.10.2022
SM19.10.2022
IS19.02.2023
Former [2023/48]AL19.10.2022
AT19.10.2022
EE19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
MC19.10.2022
PL19.10.2022
RO19.10.2022
RS19.10.2022
SE19.10.2022
SK19.10.2022
SM19.10.2022
IS19.02.2023
Former [2023/38]AL19.10.2022
AT19.10.2022
EE19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
PL19.10.2022
RO19.10.2022
RS19.10.2022
SE19.10.2022
SK19.10.2022
SM19.10.2022
IS19.02.2023
Former [2023/37]AL19.10.2022
AT19.10.2022
EE19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
PL19.10.2022
RO19.10.2022
RS19.10.2022
SE19.10.2022
SM19.10.2022
IS19.02.2023
Former [2023/35]AT19.10.2022
EE19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
PL19.10.2022
RO19.10.2022
RS19.10.2022
SE19.10.2022
SM19.10.2022
IS19.02.2023
Former [2023/34]AT19.10.2022
EE19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
PL19.10.2022
RS19.10.2022
SE19.10.2022
SM19.10.2022
IS19.02.2023
Former [2023/33]AT19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
PL19.10.2022
RS19.10.2022
SE19.10.2022
SM19.10.2022
IS19.02.2023
Former [2023/25]AT19.10.2022
FI19.10.2022
HR19.10.2022
LT19.10.2022
LV19.10.2022
PL19.10.2022
RS19.10.2022
SE19.10.2022
IS19.02.2023
Former [2023/23]AT19.10.2022
FI19.10.2022
LT19.10.2022
LV19.10.2022
SE19.10.2022
Former [2023/22]AT19.10.2022
FI19.10.2022
LT19.10.2022
SE19.10.2022
Former [2023/20]LT19.10.2022
Documents cited:Search[A]WO2007081974  (ROMARK LAB LC [US], et al) [A] 1-9 * example -; claim -; table - *;
 [A]US2011177999  (SINGH ASHVANI [US], et al) [A] 1-9 * paragraph [0058]; claim - *;
 [A]WO2013059879  (FLOREY HOWARD INST [AU], et al) [A] 1-9* claim - *;
 [A]  - P. PATRICK BASU ET AL, "Effects of triple-drug therapy with nitazoxanide, high-dose ribavirin and peginterferon-[alpha]-2a in patients with chronic hepatitis C", HEPATOLOGY RESEARCH, NL, (20121211), vol. 43, no. 6, doi:10.1111/hepr.12013, ISSN 1386-6346, pages 589 - 595, XP055302495 [A] 1-9 * discussion *

DOI:   http://dx.doi.org/10.1111/hepr.12013
 [A]  - KORBA ET AL, "Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, (20080101), vol. 77, no. 1, doi:10.1016/J.ANTIVIRAL.2007.08.005, ISSN 0166-3542, pages 56 - 63, XP022405848 [A] 1-9 * discussion *

DOI:   http://dx.doi.org/10.1016/j.antiviral.2007.08.005
by applicant   - A WADOUACHIJ KOVENSKY, Synthesis of Glycosides of Glucuronic, Galacturonic and Mannuronic Acids: An Overview, Molecules, (20110000), vol. 16, no. 5, pages 3933 - 3968
    - BROEKHUYSEN, J.A. STOCKIS et al., "Nitazoxanide: pharmacokinetics and metabolism in man", Int J Clin Pharmacol Ther, (20000000), vol. 38, no. 8, pages 387 - 394
    - "Nitazoxanide disrupts membrane potential and intrabacterial pH homeostasis of Mycobacterium tuberculosis", DE CARVALHO, L. P. S.C. M. DARBY et al., ACS Med. Chem. Lett., American Chemical Society (ACS, (20110000), vol. 2, pages 849 - 854
    - "A functional perspective of nitazoxanide as a potential anticancer drug", DI SANTO, N.J. EHRISMAN, Mutat. Res., Fundam. Mol. Mech. Mutagen, American Chemical Society (ACS, (20140000), vol. 768, pages 16 - 21
    - "Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora", FINEGOLD, S. M.D. MOLITORIS et al., Antimicrob. Agents Chemother., American Chemical Society (ACS, (20150000), vol. 50, pages 1112 - 1117
    - "Nitazoxanide: a new thiazolide antiparasitic agent", FOX, L. M.L. D. SARAVOLATZ, Clin. Infect. Dis., American Chemical Society (ACS, (20050000), vol. 40, pages 1173 - 1180
    - "Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections", HEMPHILL, A.J. MUELLER et al., Expert Opin. Pharmacother., American Chemical Society (ACS, (20060000), vol. 7, pages 953 - 964
    - KENDALL, R. T.C. A. FEGHALI-BOSTWICK, "Fibroblasts in fibrosis: novel roles and mediators", Front Pharmacol, (20140000), vol. 5, page 123
    - LEASK, A., "TGFbeta, cardiac fibroblasts, and the fibrotic response", Cardiovasc Res, (20070000), vol. 74, no. 2, pages 207 - 212
    - LEASK, A.D. J. ABRAHAM, "TGF-beta signaling and the fibrotic response", FASEB J, (20040000), vol. 18, no. 7, pages 816 - 827
    - ROSENBLOOM, J.F. A. MENDOZA et al., "Strategies for anti-fibrotic therapies", Biochim Biophvs Acta, (20130000), vol. 1832, no. 7, doi:10.1016/j.bbadis.2012.12.007, pages 1088 - 1103, XP028589920

DOI:   http://dx.doi.org/10.1016/j.bbadis.2012.12.007
    - "Nitazoxanide: A first-in-class broad-spectrum antiviral agent", ROSSIGNOL, J.-F., Antiviral Res., American Chemical Society (ACS, (20140000), vol. 110, pages 94 - 103
    - ROSSIGNOL, J. F.R. CAVIER, "2-Benzamido-5-nitrothiazoles", S.P.R.L. Phavic, Belg., (19750000), page 11
    - "Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections", ROSSIGNOL, J. F.H. MAISONNEUVE, Am J Trop Med Hyg, U.S. National Library of Medicine, (19840000), vol. 33, pages 511 - 512
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.